JP2024514708A - フォンウィルブランド因子(vwf)阻害剤 - Google Patents

フォンウィルブランド因子(vwf)阻害剤 Download PDF

Info

Publication number
JP2024514708A
JP2024514708A JP2023565152A JP2023565152A JP2024514708A JP 2024514708 A JP2024514708 A JP 2024514708A JP 2023565152 A JP2023565152 A JP 2023565152A JP 2023565152 A JP2023565152 A JP 2023565152A JP 2024514708 A JP2024514708 A JP 2024514708A
Authority
JP
Japan
Prior art keywords
seq
chain variable
antibody
antigen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565152A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022223966A5 (https=
JP2024514708A5 (https=
Inventor
クレモ,ナディーン
ルイス,アラン
マッキノン,トム
Original Assignee
アイピー2アイピーオー イノベ-ションズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイピー2アイピーオー イノベ-ションズ リミテッド filed Critical アイピー2アイピーオー イノベ-ションズ リミテッド
Publication of JP2024514708A publication Critical patent/JP2024514708A/ja
Publication of JPWO2022223966A5 publication Critical patent/JPWO2022223966A5/ja
Publication of JP2024514708A5 publication Critical patent/JP2024514708A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/755Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023565152A 2021-04-20 2022-04-20 フォンウィルブランド因子(vwf)阻害剤 Pending JP2024514708A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2105625.4A GB202105625D0 (en) 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors
GB2105625.4 2021-04-20
PCT/GB2022/050989 WO2022223966A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors

Publications (3)

Publication Number Publication Date
JP2024514708A true JP2024514708A (ja) 2024-04-02
JPWO2022223966A5 JPWO2022223966A5 (https=) 2025-03-26
JP2024514708A5 JP2024514708A5 (https=) 2025-03-26

Family

ID=76377797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565152A Pending JP2024514708A (ja) 2021-04-20 2022-04-20 フォンウィルブランド因子(vwf)阻害剤

Country Status (12)

Country Link
US (1) US20240228660A1 (https=)
EP (1) EP4326778A1 (https=)
JP (1) JP2024514708A (https=)
KR (1) KR20240004332A (https=)
CN (1) CN117597367A (https=)
AU (1) AU2022262695A1 (https=)
BR (1) BR112023021631A2 (https=)
CA (1) CA3214716A1 (https=)
GB (1) GB202105625D0 (https=)
IL (1) IL307441A (https=)
MX (1) MX2023012391A (https=)
WO (1) WO2022223966A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202215432D0 (en) * 2022-10-19 2022-11-30 Ip2Ipo Innovations Ltd Von Willebrand factor (VWF) antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510622A (ja) * 2008-01-23 2011-04-07 グレンマーク ファーマシューティカルズ エスアー フォンウィレブランド因子に特異的なヒト化抗体
EP2543678A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510622A (ja) * 2008-01-23 2011-04-07 グレンマーク ファーマシューティカルズ エスアー フォンウィレブランド因子に特異的なヒト化抗体
EP2543678A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
宮田 茂樹: "GPIb結合ドメインならびにC末端部分を認識する抗von Willebrand因子(vWF)モノクローナル抗体を用い", 奈良医学雑誌, vol. 42, no. 5, JPN6026011347, 1991, pages 437 - 448, ISSN: 0005821260 *

Also Published As

Publication number Publication date
US20240228660A1 (en) 2024-07-11
MX2023012391A (es) 2024-02-02
CN117597367A (zh) 2024-02-23
KR20240004332A (ko) 2024-01-11
IL307441A (en) 2023-12-01
EP4326778A1 (en) 2024-02-28
WO2022223966A1 (en) 2022-10-27
CA3214716A1 (en) 2022-10-27
GB202105625D0 (en) 2021-06-02
AU2022262695A1 (en) 2023-10-05
BR112023021631A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
CA2698382C (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
TW201132353A (en) WISE binding agents and epitopes
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
KR20230119693A (ko) 면역글로불린 경쇄 항체 및 이의 용도
JP2019510474A (ja) トロンビン抗体、その抗原結合フラグメント及び医薬用途
US20230357387A1 (en) Zip12 antibody
EP3577136A1 (en) Inhibition of platelet aggregation using anti-human gpvi antibodies
US20240228660A1 (en) Von willebrand factor (vwf) inhibitors
EP4605078A1 (en) Von willebrand factor (vwf) antibody
US12448441B2 (en) ZIP12 antibody
WO2023143564A1 (en) Antibody against btla and uses thereof
CN121175339A (zh) 抗fxi抗体及其用途
WO2025172587A1 (en) Binding constructs
WO2025172588A1 (en) Bispecific constructs directed against fap and ltbr
JP2024523846A (ja) 抗masp-2抗体及びその使用
HK40114352A (zh) 针对btla的抗体及其用途
HK1230217A1 (en) Antibody binding to fcrn for treating autoimmune diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260323